Valeant Announces First-Quarter 2018 Results And Raises Revenue And Adjusted EBITDA (non-GAAP) Guidance

FREE Breaking News Alerts from StreetInsider.com!

E-mail Address

StreetInsider.com Top Tickers, 6/24/2026

1. SPCX
2. FDX
3. META
4. ABBV
5. SPY
6. IBM
7. NKE
8. MU
9. PFE
10. AWK

Go back to Valeant Announces First-Quarter 2018 Results And Raises Revenue And Adjusted EBITDA (non-GAAP) Guidance

Valeant Pharmaceuticals (VRX): 'A Turnaround For The Ages' - Cantor Fitzgerald

May 8, 2018 2:15 PM EDT

Cantor Fitzgerald analyst Louise Chen reiterated an Overweight rating and $25 price target on Valeant Pharmaceuticals (NYSE: VRX) following Q1 beat and raise.

"We think a greater appreciation for Valeant's solid execution and future growth prospects should drive upwards earnings revisions as well as multiple expansion in 2019+,"... More